Mounjaro becomes available on Gesy for obesity and diabetes

State-Subsidized Mounjaro Rollout Under Gesy

Adults meeting strict clinical criteria for obesity treatment and patients diagnosed with Type 2 diabetes became eligible for state-subsidized access to the weight-loss and diabetes medication Mounjaro starting October 15. The inclusion under the General Healthcare System (Gesy) introduces another pharmacological option for individuals managing complex health conditions, though access requires prior authorization and meeting specific medical requirements.

For patients such as 45-year-old Alexandra Monis from Larnaca, who has struggled with a combination of depression, irregular periods, muscle and joint pain, sciatica, and persistent migraines alongside obesity, the announcement arrives after years of fragmented guidance. Monis stated that navigating between doctors and dieticians without cohesive feedback proved exhausting. Under the updated protocols, qualifying for the newly reimbursed therapy demands a rigorous clinical assessment.

Strict Diagnostic Thresholds and Specialist Prescriptions

Reimbursement under Gesy is not automatic and depends on strict diagnostic thresholds. For obesity treatment, adults must present a body mass index (BMI) of at least 40. Those with a BMI of 35 to below 40 may also qualify if they have established atherosclerotic cardiovascular disease or moderate to severe obstructive sleep apnea.

Prescriptions are strictly restricted to designated specialists. These include endocrinology, specialist pathology, geriatrics, and designated adult general medicine practitioners.

State Hospital Distribution and Ozempic Protocols

During the initial rollout phase, Mounjaro is dispensed exclusively through state hospital pharmacies. Meanwhile, Ozempic remains available through private pharmacies under a revised protocol for Type 2 diabetes.

The updated Gesy guidelines position Ozempic as the first-choice option between the two medications for patients with Type 2 diabetes, regardless of their body weight.

Pharmacological Differences and Individual Responses

Although both Mounjaro and Ozempic are used to treat Type 2 diabetes, they work differently. Mounjaro contains tirzepatide, which acts on two hormone receptors involved in blood sugar regulation and appetite, whereas semaglutide in Ozempic acts on one. Clinical trials indicate that tirzepatide can produce greater average weight loss than semaglutide in specific comparisons, though individual patient outcomes vary widely.

Patient experiences reported highlight contrasting responses. A 27-year-old man recently diagnosed with Type 2 diabetes lost 5kg during his first two weeks on Mounjaro, managing initial diarrhea that subsided quickly. Conversely, a 58-year-old woman taking Ozempic reported a 0.7 percentage point drop in her HbA1c levels alongside fatigue, anxiety, insomnia, and abdominal bloating without experiencing weight loss.

Gastrointestinal Risks and Two-Year Treatment Caps

Commonly recognized side effects for both medicines include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Severe gastrointestinal distress can impair food and fluid intake, elevating the risk of dehydration and requiring prompt medical evaluation. An unnamed endocrinologist emphasized that patients must undergo a thorough nutritional assessment before starting treatment to evaluate lifestyle measures and understand potential gastrointestinal risks.

Long-term management remains a critical concern for treating physicians, who warn that appetite often returns and weight may increase after discontinuing injections. Treatment under Gesy reimbursement may be reimbursed for up to two years, provided patients continue to meet the clinical criteria.

More on Mounjaro: Mounjaro tapering linked to hair loss via telogen effluvium